Rituximab in pemphigus and pemphigoid patients: Treatment outcomes and safety profile - A 6-year tertiary center study
DOI:
https://doi.org/10.71152/ajms.v16i7.4588Keywords:
CD20; Adverse drug reactions; Autoimmune disorders; Remission; Dermatology; Blistering diseasesAbstract
Background: Pemphigus and pemphigoid are autoimmune blistering disorders characterized by autoantibodies attacking skin and mucous membranes. Rituximab, targeting CD20-positive B cells, has emerged as a treatment option for resistant cases.
Aims and Objectives: To evaluate the treatment outcomes and safety profile of rituximab in patients with pemphigus and pemphigoid diseases treated at a tertiary care center over 6 years.
Materials and Methods: This retrospective study analyzed the outcomes of 23 patients treated with rituximab for pemphigus and pemphigoid diseases at a tertiary care hospital between February 2017 and February 2023. Data included demographics, disease characteristics, treatment specifics, and adverse reactions. Treatment response was evaluated using the Nikolsky sign, and the World Health Organization causality assessment scale classified adverse events. Statistical analysis was conducted with SPSS version 25.0.
Results: The study included 23 patients (52.2% male), with a mean age of 50.48 years. Majority of the patients were diagnosed with pemphigus vulgaris (60.9%). Of the 23 patients, 17 (73.9%) achieved complete remission, while 6 (26.1%) attained partial remission. Most patients (43.5%) required two cycles of rituximab, with complete remission achieved after two cycles in 52.9% of those in remission. Patients with partial remission required more infusions, with 33.3% receiving three or more cycles. Adverse drug reactions (ADRs) were observed in 5 patients (21.7%), all of whom experienced mild, infusion-related symptoms, such as pruritus (8.7%) and dyspnea (4.3%). A significant association between gender and ADRs was found, with females more prone to ADRs (P=0.008). No severe reactions were reported, and all ADRs were resolved.
Conclusion: Rituximab shows high efficacy in inducing remission in pemphigus and pemphigoid patients, with a manageable safety profile. Individualized treatment regimens, including the number of cycles, may optimize outcomes.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Asian Journal of Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
